You are on our international English website. This site features our entire product portfolio worldwide. The products featured may not be available in the US. If you are a citizen from the US, please visit your country website for local information and contacts.
Medical Technology for healthcare professionals
Global website (English)
back
Medical Technology
recommended searches
popular searches
ZEISS IORT Insights

ZEISS IORT Insights

Clinical advancements in brain tumor treatment
ZEISS IORT Insights
Stay up to Date

Welcome to your essential hub for the latest advancements and insights in intraoperative radiotherapy (IORT) for brain tumor treatment – ZEISS IORT Insights.

Tailored specifically for brain tumor experts, we will feed you here with regular updates on new clinical findings, latest peer-to-peer experiences, interesting knowledge sharing and downloadable resources in various formats which you can easily share in your teams - always at your fingertips.

Stay up to date and enrich your daily practice with the latest insights in IORT for brain tumor treatments and beyond. Enjoy your journey!

Study Spotlight: IORT after neurosurgical resection of brain metastases
Study Spotlight: IORT after neurosurgical resection of brain metastases

Study Spotlight: IORT after neurosurgical resection of brain metastases

Intraoperative radiotherapy (IORT) offers a compelling alternative to conventional external radiotherapy modalities for the treatment of brain metastases, gaining increasing traction in the last years.

The recently published paper by Kahl, K. H., et. al (2024)1 presents the impact of IORT on oncological outcome and toxicity after neurosurgical resection of brain metastases in a high-volume setting. This experience of a single center cohort showcases how 105 patients with a total of 117 resected brain metastases have been treated with IORT at a median dose of 20 Gy prescribed to the surface of the applicator.

The results are promising and IORT appears to be a safe way with low toxicity and excellent local control. Discover the key findings at a glance in our concise study spotlight!

Complete the form below and download your study spotlight
ZEISS IORT Insights Infographic

Infographic about IORT in brain tumor treatment

What are the effects of Intraoperative Radiotherapy (IORT) on time and precision in brain tumor treatment?

Conventional external radiotherapy modalities imply treatment pitfalls, such as a relatively broad radiation reach potentially affecting healthy tissue2,3 or the need for a delayed start of radiotherapy after resection favoring a growth of residual tumor cells4,5. Intraoperative radiotherapy presents an alternative treatment option with the potential to minimize these pitfalls already today.

Learn about recent study results on IORT and its possible effects for the treatment of brain tumors and metastases today.

Update about IORT for brain metastases – time to systemic treatment is key

As time is an important factor for the treatment of brain metastases, Dejonckheere, C. S., et al. (2023)6 focused on gathering data of meaningful secondary endpoints, such as time to next treatment (TTNT = number of days between BM resection and next extracranial oncological therapy) and in-hospital time. A monocenter, prospective study registry compared 62 patients undergoing IORT (30 Gy) with 52 patients receiving adjuvant stereotactic radiotherapy (SRT) of the resection cavity.

✔ Mean TTNT was 36 days for IORT patients versus 52 days for SRT patients.
✔ Mean total in-hospital time for BM treatment (in- and out-patient days) was 11 days for IORT versus 19 days for SRT patients.
✔ Mean postoperative in-hospital time showed no significant difference between the IORT and SRT groups (11 versus 12 days).

IORT for brain metastases results in faster completion of interdisciplinary treatment when compared to adjuvant SRT. IORT may help to save limited treatment resources and reduce BM treatment costs as mean total in-hospital time is shorter with IORT vs. SRT.

Next event options for peer-to-peer exchange about IORT and beyond

  • AANS 2025: Power of one – impact of many

    25 – 28 April 2025

    Boston, USA
    ZEISS Booth #625

  • ESTRO 2025: Transformative innovation through partnership

    02 – 06 May 2025

    Vienna, Austria
    ZEISS Booth #400

Download study spotlight now!

Form is loading...

Personal Contact Information

Area of Expertise

If you want to have more information on data processing at ZEISS please refer to our data privacy notice.

  • 1

    Kahl, K. H., et al. (2024). Intraoperative radiotherapy after neurosurgical resection of brain metastases as institutional standard treatment – Update of the oncological outcome form a single center cohort after 117 procedures. Journal of Neuro-Oncology, 169, 187-193. DOI: 10.1007/s11060-024-04691-6.
  • 2

    Vargo, J. A., et al. (2018). Feasibility of dose escalation using intraoperative radiotherapy following resection of large brain metastases compared to postoperative stereotactic radiosurgery. Journal of Neuro-Oncology, 140(2), 413-420. DOI: 10.1007/s11060-018-2968-4.
  • 3

    Scoccianti, S., et al. (2015). Organs at risk in the brain and their dose-constraints in adults and in children: A radiation oncologist’s guide for delineation in everyday practice. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 114(2), 230-238. DOI: 10.1016/j.radonc.2015.01.016.
  • 4

    Minniti, G., et al. (2021). Current status and recent advances in resection cavity irradiation of brain metastases. Radiation Oncology, 16, 73. DOI:10.1186/s13014-021-01802-9.
  • 5

    Barker, E. H., et al. (2015). The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nature Reviews Cancer, 15(7), 409-425. DOI: 10.1038/nrc3958.
  • 6

    Dejonckheere, C. S., et al. (2023). Intraoperative or postoperative stereotactic radiotherapy for brain metastases: time to systemic treatment onset and other patient-relevant outcomes. Journal of Neuro-Oncology, 164(3), 683-691. DOI: 10.1007/s11060-023-04464-7.